Correspondence 0001213900-23-085344 from InMed Pharmaceuticals Inc. (INM)

InMed Pharmaceuticals Inc.
Date: Nov. 9, 2023 · CIK: 0001728328 · Accession: 0001213900-23-085344

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-275410

Date

November 9, 2023

Author

/s/ Eric A. Adams

Form

CORRESP

Company

InMed Pharmaceuticals Inc.

Letter

INMED PHARMACEUTICALS INC.

Suite 310 - 815 West Hastings Street

Vancouver, British Columbia, Canada

V6C 1B4

VIA EDGAR

November 9, 2023

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Re: InMed Pharmaceuticals Inc.

Acceleration Request for Registration Statement on Form S-1

Filed November 8, 2023

File No. 333-275410

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, InMed Pharmaceuticals Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to November 13, 2023, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable.

If you have any questions regarding this request, please contact Brian Fenske of Norton Rose Fulbright US LLP at (713) 651 5557.

Sincerely,
INMED PHARMACEUTICALS INC.

Show Raw Text

CORRESP
1
filename1.htm

INMED PHARMACEUTICALS INC.

Suite 310 - 815 West Hastings Street

Vancouver, British Columbia, Canada

V6C 1B4

VIA EDGAR

November 9, 2023

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Re: InMed Pharmaceuticals Inc.

Acceleration Request for Registration Statement on Form S-1

Filed November 8, 2023

File No. 333-275410

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended,
InMed Pharmaceuticals Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated
to November 13, 2023, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable.

If you have any questions regarding this request, please contact Brian
Fenske of Norton Rose Fulbright US LLP at (713) 651 5557.

    Sincerely,

    INMED PHARMACEUTICALS INC.

    /s/ Eric A. Adams

    Eric A. Adams

    President and Chief Executive Officer

 cc: Jonathan Tegge, InMed Pharmaceuticals Inc.

Brian Fenske, Norton Rose Fulbright US LLP

SecProbe.io